Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subject Age ≥ 18 years of age
• Patient diagnosed with dyspepsia
• Present at the ED with upper abdominal pain score of at least 3
Locations
United States
New York
Stony Brook University Hospital
RECRUITING
Stony Brook
Contact Information
Primary
Adam Singer, MD
adam.singer@stonybrookmedicine.edu
6314447857
Time Frame
Start Date: 2023-11-09
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 80
Treatments
Active_comparator: Intravenous Famotidine
Patients in this group will receive 20 mg of intravenous famotidine.
Active_comparator: Oral Maalox
Patients in the group will receive 30 ml of oral Maalox/ Mylanta.
Related Therapeutic Areas
Sponsors
Leads: Stony Brook University